GSK’s drops chronic cough drug, dampening $2bn Bellus Health bid
GSK’s $2bn bid on Bellus Health has taken a knock, as the British pharma giant is terminating the late-stage refractory…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
AAIC26: Roche charts expanded course for Alzheimer’s therapy, touts long-term anti-amyloid impact
Roche is eyeing a wider patient population for its anti-amyloid Alzheimer’s hopeful, trontinemab, as the space increasingly examines the potential…
-
AAIC26: Community co-development to guide next generation of diverse trials
Despite progress in bolstering the diversity of clinical trials within the Alzheimer’s disease space, significant barriers to true study diversity…
-
NewAmsterdam’s cholesterol-lowering therapy shows Alzheimer’s promise
NewAmsterdam’s low-density lipoprotein (LDL) cholesterol-lowering therapy, obicetrapib, has shown promise in diminishing a key biomarker of Alzheimer’s disease – potentially…
-
Ipsen set to rival Botox after duo of Phase III migraine wins
Ipsen Pharmaceuticals’ Dysport (abobotulinumtoxinA), a Botox (onabotulinumtoxinA) competitor, could be on track for a label expansion after the drug posted…
-
Keenova seeks Xiaflex expansion on late-stage rare disease win
Keenova Therapeutics is hoping to step into a new market with Xiaflex (collagenase clostridium histolyticum), after the drug netted a…
-
Teva draws up mid-stage study plans for vitiligo asset on Phase Ib success
Teva is planning to progress its anti-IL-15 therapy, TEV-‘408 into a Phase IIb trial in vitiligo after the drug demonstrated…
-
Kailera points to Phase III oral obesity drug data as it tees up Foundayo rivalry
Kailera Therapeutics’ bet on Hengrui Pharma’s oral glucagon-like peptide 1 receptor agonist (GLP-1RA) appears to be paying off following two…
-
Local artery blocking device cuts knee osteoarthritis pain by 57%, study reveals
NextBiomedical’s artery-blocking device, Nexsphere-F, has significantly improved outcomes in patients with knee osteoarthritis in a European clinical study – a…
-
WHO intensifies Ebola-curbing efforts through drug trial and diagnostic rollout
The World Health Organization (WHO) has taken fresh steps to curb the rising Ebola epidemic in central Africa caused by…